<![CDATA[FDA Approves Subcutaneous Isatuximab in Multiple Myeloma]]>
Read the full article3h agoen
You might also wanna read
<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>
Pharmacy Times·1h ago
<![CDATA[Pharmacist-Led Workflows Support Safe Outpatient BiTE Therapy in Multiple Myeloma]]>
Pharmacy Times·2d ago
<![CDATA[Outpatient BiTE Therapy Model Expands Access for Patients With Multiple Myeloma]]>
Pharmacy Times·2d ago
<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>
Pharmacy Times·1d ago
<![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]>
Pharmacy Times·1d ago
<![CDATA[FDA Approves Atacicept-vymj to Reduce Proteinuria in IgA Nephropathy]]>
Pharmacy Times·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.